Skip to main
LFCR

LFCR Stock Forecast & Price Target

LFCR Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lifecore Biomedical has experienced growth in its HA manufacturing segment, predominantly due to favorable order timing from its largest customer, resulting in a 9.8% increase in revenue in the latest quarter compared to the previous year. The company projects a significant increase in developmental revenue over the next few years, targeting 60% capacity utilization by 2029, which suggests a robust growth trajectory from its current 20% utilization level in 2025. Additionally, Lifecore has successfully secured three commercial site transfer programs in the last five months, indicating its increasing appeal as a manufacturing partner and reinforcing expectations of operational momentum that could contribute to a projected revenue CAGR of 12% by 2029.

Bears say

Lifecore Biomedical has experienced a significant drop in share price, declining over 50% in the past two months, primarily attributed to disappointing fiscal year 2026 guidance and conservative expectations for fiscal year 2027 growth. The company's revenue challenges stem from a notable decline in contract development and manufacturing (CDMO) revenue, influenced by a key customer loss, inventory rebalancing by a major client, and delayed product launches related to customer funding issues. While there was modest growth in hyaluronic acid (HA) manufacturing revenue, the overall financial outlook remains clouded by concerns over future capital needs and the potential for additional revenue headwinds.

LFCR has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lifecore Biomedical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lifecore Biomedical Inc (LFCR) Forecast

Analysts have given LFCR a Buy based on their latest research and market trends.

According to 1 analysts, LFCR has a Buy consensus rating as of Mar 31, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lifecore Biomedical Inc (LFCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.